These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 25655767)

  • 21. [Adolescents with concurrent ADHD and substance use disorder; international consensus].
    Spijkerman R; Crunelle CL; Özgen MH; Begeman AHA; Dom G; van de Glind G; Groenman AP; van Kernebeek MW; Matthys F; Post M; Schellekens A; Staal W; van den Brink W; Hendriks VM
    Tijdschr Psychiatr; 2021; 63(12):868-874. PubMed ID: 34978058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment strategies for co-occurring ADHD and substance use disorders.
    Mariani JJ; Levin FR
    Am J Addict; 2007; 16 Suppl 1(Suppl 1):45-54; quiz 55-6. PubMed ID: 17453606
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Effects of Long-Acting Stimulant and Nonstimulant Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Meta-Analysis of Randomized Controlled Trials.
    Cerrillo-Urbina AJ; García-Hermoso A; Pardo-Guijarro MJ; Sánchez-López M; Santos-Gómez JL; Martínez-Vizcaíno V
    J Child Adolesc Psychopharmacol; 2018 Oct; 28(8):494-507. PubMed ID: 29897263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of comorbid substance use disorder during long-term central stimulant treatment in adult ADHD.
    Torgersen T; Gjervan B; Rasmussen K; Vaaler A; Nordahl HM
    Atten Defic Hyperact Disord; 2013 Mar; 5(1):59-67. PubMed ID: 23104523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature.
    Wilens TE; Adler LA; Adams J; Sgambati S; Rotrosen J; Sawtelle R; Utzinger L; Fusillo S
    J Am Acad Child Adolesc Psychiatry; 2008 Jan; 47(1):21-31. PubMed ID: 18174822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnosis and treatment of patients with comorbid substance use disorder and adult attention-deficit and hyperactivity disorder: a review of recent publications.
    van der Burg D; Crunelle CL; Matthys F; van den Brink W
    Curr Opin Psychiatry; 2019 Jul; 32(4):300-306. PubMed ID: 31008730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized controlled trial of pemoline for attention-deficit/hyperactivity disorder in substance-abusing adolescents.
    Riggs PD; Hall SK; Mikulich-Gilbertson SK; Lohman M; Kayser A
    J Am Acad Child Adolesc Psychiatry; 2004 Apr; 43(4):420-9. PubMed ID: 15187802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The complicated relationship between attention deficit/hyperactivity disorder and substance use disorders.
    Zulauf CA; Sprich SE; Safren SA; Wilens TE
    Curr Psychiatry Rep; 2014 Mar; 16(3):436. PubMed ID: 24526271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinical course of comorbid substance use disorder and attention deficit/hyperactivity disorder: protocol and clinical characteristics of the INCAS study.
    Brynte C; Aeschlimann M; Barta C; Begeman AHA; Bäcker A; Crunelle CL; Daigre C; De Fuentes-Merillas L; Demetrovics Z; Dom G; López LG; Icick R; Johnson B; Joostens P; Kapitány-Fövény M; Karsinti E; Kiefer F; Konstenius M; Levin FR; Luderer M; Markus W; Matthys F; Moggi F; Palma-Alvarez RF; Paraskevopoulou M; Ramos-Quiroga JA; Schellekens A; Soravia LM; Therribout N; Thomas A; van de Glind G; van Kernebeek MW; Vollstädt-Klein S; Vorspan F; van den Brink W; Franck J
    BMC Psychiatry; 2022 Sep; 22(1):625. PubMed ID: 36151539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacotherapeutic strategies for the treatment of attention-deficit hyperactivity (ADHD) disorder with comorbid substance-use disorder (SUD).
    Perugi G; Pallucchini A; Rizzato S; De Rossi P; Sani G; Maremmani AG; Pinzone V; Maremmani I
    Expert Opin Pharmacother; 2019 Feb; 20(3):343-355. PubMed ID: 30513231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder.
    Biederman J; Wilens T; Mick E; Spencer T; Faraone SV
    Pediatrics; 1999 Aug; 104(2):e20. PubMed ID: 10429138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prescription Stimulant Nonmedical Use Among Adolescents Evaluated for Substance Use Disorder Treatment (CHAT™).
    Vosburg SK; Faraone SV; Newcorn JH; Rostain AL; Findling RL; Butler SF; Govoni TD; Green JL
    J Atten Disord; 2021 Nov; 25(13):1859-1870. PubMed ID: 32697138
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence.
    Cunill R; Castells X; Tobias A; Capellà D
    J Psychopharmacol; 2015 Jan; 29(1):15-23. PubMed ID: 25142405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Substance use disorders and ADHD: an overview of recent Dutch research].
    van Emmerik-van Oortmerssen K; Crunelle CL; Carpentier PJ
    Tijdschr Psychiatr; 2013; 55(11):861-6. PubMed ID: 24242145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Substance Misuse and Family History of Substance Use Disorder on Delay Discounting in Adolescents and Young Adults with Attention-Deficit/Hyperactivity Disorder.
    Paraskevopoulou M; van Rooij D; Schene AH; Scheres APJ; Buitelaar JK; Schellekens AFA
    Eur Addict Res; 2020; 26(4-5):295-305. PubMed ID: 32659779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ADHD, Conduct Disorder, Substance Use Disorder, and Nonprescription Stimulant Use.
    Brook JS; Balka EB; Zhang C; Brook DW
    J Atten Disord; 2017 Jul; 21(9):776-782. PubMed ID: 24776714
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Attention Deficit/Hyperactivity Disorder and Global Severity Profiles in Treatment-Seeking Patients with Substance Use Disorders.
    Icick R; Moggi F; Slobodin O; Dom G; Mathys F; van den Brink W; Levin FR; Blankers M; Kaye S; Demetrovics Z; van de Glind G; Velez-Pastrana MC; Schellekens ASA;
    Eur Addict Res; 2020; 26(4-5):201-210. PubMed ID: 32570249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Attention-deficit/hyperactivity disorder subtypes in adolescents with comorbid substance-use disorder.
    Tamm L; Adinoff B; Nakonezny PA; Winhusen T; Riggs P
    Am J Drug Alcohol Abuse; 2012 Jan; 38(1):93-100. PubMed ID: 21834613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The dark side of ADHD - comorbidity with substance use disorder and criminality - an overview].
    Johansson Capusan A; Guterstam J; Ginsberg Y; Borg Skoglund L
    Lakartidningen; 2022 Feb; 119():. PubMed ID: 36794414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder.
    Perugi G; Vannucchi G
    Expert Opin Pharmacother; 2015; 16(14):2193-204. PubMed ID: 26364896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.